Evidence map›Paper›PMID 41716290›Full record

ArticleFrontiers in cell and developmental biology2026

A prospective pilot study on DACHAO intervention for improving embryo quality metrics in IVF/ICSI failure cases.

Rui Xing, Lei Jiang, Jie Zhang, Xiao-Qi Zuo, Xin Xu, Meng-Chi Xue, Yi-Ran Zhao, Gui-Min Hao

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rui XingDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Lei JiangDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Jie ZhangDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xiao-Qi ZuoDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Xin XuDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Meng-Chi XueDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Yi-Ran ZhaoDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Gui-Min HaoDepartment of Reproductive Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research question: Embryo quality serves as a pivotal determinant in assisted reproductive technology (ART) outcomes, with high-grade embryos correlating with improved pregnancy/live birth rates but poor morphology elevating the risks of implantation failure and pregnancy loss. Despite its clinical significance, therapeutic options for enhancing embryo development remain limited, necessitating novel interventions to improve poor embryogenesis. Objective: This study aimed to evaluate the efficacy of DACHAO Reco18-a formulation containing natural extracts of clove, Sophora flower bud, and yam-in improving reproductive outcomes among IVF patients with a history of poor embryo quality. Design: This was a prospective self-controlled study, to assess the effects of DACHAO Reco18 containing natural extracts of clove, Sophora flower bud, and yam on reproductive outcomes in 68 IVF patients (aged 20-40 years) with a history of IVF/ICSI failure and documented poor embryo quality (≤20% high-grade embryos and no surplus embryos). All participants had previously undergone IVF/ICSI treatment at our center between January 2022 and December 2023. Over 6 weeks of oral treatment, outcomes were compared between pre- and post-intervention cycle. The primary outcome measure was embryo parameters, while secondary outcomes encompassed oocyte yield, fertilization efficiency, implantation rate and pregnancy rate. Results: DACHAO Reco18 intervention significantly improved the mean oocyte yield from 7.955 to 8.955 oocytes retrieved per cycle, fertilization outcomes with 2 pronucleus (PN) zygotes increasing from 3.731 to 5.463 embryos, and Day-3 embryo enhancement from 1.896 to 3.000 viable embryos. High-quality embryos surged by 118.52% from 0.567 to 1.239, with the quality rate improving from 30.729% to 44.107%. Additionally, when compared to the pre-treatment cycle, the post-treatment cycle showed statistically significant improvements in the implantation rate (0%-32.00%), biochemical pregnancy (0%-24.00%) and clinical pregnancy (0%-21.05%). Subgroup analyses revealed FSH reduction in hyper-gonadotropic patients (from 12.083 to 9.941 mIU/mL). Conclusion: This prospective self-controlled study suggests that a six-week DACHAO Reco18 intervention is associated with improved ovarian response and embryological outcomes in IVF patients with poor embryo quality, including reduced FSH in hyper-gonadotropic individuals. While promising, these preliminary findings warrant verification through randomized controlled trials to evaluate its potential as an adjuvant treatment in ART.

Indexed as

2PN rateDACHAO reco18embryo qualityimplantation rateIVF/ICSIpregnancy rate

Identifiers

PMID41716290
PMCPMC12913368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.